Literature DB >> 7829860

Selective assay for CyPA and CyPB in human blood using highly specific anti-peptide antibodies.

F Allain1, C Boutillon, C Mariller, G Spik.   

Abstract

Cyclophilins A and B (CyPA and CyPB) are known to be the main binding proteins for cyclosporin A (CsA), a potent immunosuppressive drug. Due to the high homology between the two proteins, antibodies to CyPB were found to cross-react with CyPA. In order to avoid this phenomenon, we raised specific antibodies against peptides copying the most divergent parts of the two sequences. These antibodies allowed us to develop an ELISA capture assay selective for either isotype. Thus, we showed that leukocyte CyPB concentration was almost ten times lower than that of CyPA, and that in contrast to the results described in the literature, only CyPB was released in plasma. Moreover, CyPB levels in leukocytes and plasma were found to correlate for the same donor, but no relationship was found with CyPA level.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7829860     DOI： 10.1016/0022-1759(94)00249-v

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN： 0022-1759            Impact factor:   2.303


  19 in total

1.  Elevated serum cyclophilin levels in patients with severe sepsis.

Authors:  I Tegeder; A Schumacher; S John; H Geiger; G Geisslinger; H Bang; K Brune
Journal:  J Clin Immunol       Date:  1997-09       Impact factor: 8.317

2.  Distribution of cyclophilin B-binding sites in the subsets of human peripheral blood lymphocytes.

Authors:  A Denys; F Allain; B Foxwell; G Spik
Journal:  Immunology       Date:  1997-08       Impact factor: 7.397

3.  Involvement of the N-terminal part of cyclophilin B in the interaction with specific Jurkat T-cell binding sites.

Authors:  C Mariller; B Haendler; F Allain; A Denys; G Spik
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

4.  Cyclophilin B mediates cyclosporin A incorporation in human blood T-lymphocytes through the specific binding of complexed drug to the cell surface.

Authors:  F Allain; A Denys; G Spik
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

5.  Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention.

Authors:  William M Gwinn; Jesse M Damsker; Rustom Falahati; Ifeanyi Okwumabua; Ann Kelly-Welch; Achsah D Keegan; Christophe Vanpouille; James J Lee; Lindsay A Dent; David Leitenberg; Michael I Bukrinsky; Stephanie L Constant
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

6.  A cyclosporin derivative discriminates between extracellular and intracellular cyclophilins.

Authors:  Miroslav Malesević; Jan Kühling; Frank Erdmann; Molly A Balsley; Michael I Bukrinsky; Stephanie L Constant; Gunter Fischer
Journal:  Angew Chem Int Ed Engl       Date:  2010       Impact factor: 15.336

7.  Expression of cyclophilin B is associated with malignant progression and regulation of genes implicated in the pathogenesis of breast cancer.

Authors:  Feng Fang; Ayanna J Flegler; Pan Du; Simon Lin; Charles V Clevenger
Journal:  Am J Pathol       Date:  2008-12-04       Impact factor: 4.307

Review 8.  Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics.

Authors:  V Yurchenko; S Constant; E Eisenmesser; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2010-03-16       Impact factor: 4.330

9.  Involvement of two classes of binding sites in the interactions of cyclophilin B with peripheral blood T-lymphocytes.

Authors:  A Denys; F Allain; M Carpentier; G Spik
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

10.  Determination of the Full Catalytic Cycle among Multiple Cyclophilin Family Members and Limitations on the Application of CPMG-RD in Reversible Catalytic Systems.

Authors:  Michael J Holliday; Geoffrey S Armstrong; Elan Z Eisenmesser
Journal:  Biochemistry       Date:  2015-09-11       Impact factor: 3.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.